Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Lymphoma, T-Cell, Peripheral 2Lymphoma, T-Cell 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large-Cell, Anaplastic 1Carcinoma, Ovarian Epithelial 1

Interventions

Gemcitabine 15Cisplatin 9Paclitaxel 6Nivolumab 5Fluorouracil 4Carboplatin 4atezolizumab 3Sunitinib 3Specimen Handling 3Radiotherapy 3Doxorubicin 3pegfilgrastim 2eribulin 2cabozantinib 2avelumab 2Neoadjuvant Therapy 2Magnetic Resonance Spectroscopy 2Ipilimumab 2Ifosfamide 2Docetaxel 2CTLA-4 Antigen 2Biopsy 2vinflunine 1vandetanib 1tocilizumab 1tamibarotene 1rucaparib 1rubitecan 1romidepsin 1relatlimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Urethral Neoplasms × Depsipeptides × Clear all
NCT00087295 2012-11-02

S0400, FR901228 in Treating Patients With Advanced Cancer of the Urothelium

SWOG Cancer Research Network

Phase 2 Terminated
6 enrolled
Genitourinary

Urinary Bladder Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡